Eugene Melnyk

April 30, 2013 15:20 ET

Eugene Melnyk Sells Common Shares of Trimel Pharmaceuticals Corporation

TORONTO, ONTARIO--(Marketwired - April 30, 2013) - Mr. Eugene Melnyk announced today that he has sold 12 million common shares of Trimel Pharmaceuticals Corporation ("Trimel") through the facilities of the Toronto Stock Exchange. The shares that were sold represented approximately 8.5% of the outstanding shares of Trimel. Following the sale of these shares, Mr. Melnyk owns 41,478,965 common shares of Trimel, representing approximately 29.5% of the outstanding common shares of Trimel. The shares were sold pursuant to the exemption from the prospectus requirement set out in section 2.8 of National Instrument 45-102 - Resale of Securities. Mr. Melnyk filed the associated Form 45-102F1 on SEDAR on April 23, 2013.

Depending on market conditions and other factors, Mr. Melnyk may from time to time acquire or dispose of additional securities of Trimel in the open market, by private agreement or otherwise.

In connection with this news release, an early warning report will be filed by Mr. Melnyk in accordance with applicable securities laws. A copy of that early warning report will be available on SEDAR at www.sedar.com and can be obtained from:

Ken Villazor

25 Metcalfe Street

Toronto, ON M4X 1R5

Phone: 416-200-7641

Contact Information